NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.63

From 52W high−73.04%

Volume417052.00

Market cap$93.91M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$3.63

From 52W high

−73.04%

Volume

417052.00

Market cap

$93.91M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.1x

P/E (TTM)

—

RSI (14)

40.7

MomentumView details →

1D Return

−4.40%

YTD Return

−59.44%

SummaryUpdated Jun 1, 2026

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) is an early-stage biotechnology company founded in 2023 and headquartered in Los Angeles, California. The company went public in March 2025 through an initial public offering. Neonc focuses on developing innovative molecular technologies designed to enhance the targeted delivery of therapeutic agents for treating central nervous system diseases, particularly brain cancers. As a clinical-stage biotech company, Neonc is currently advancing its lead drug candidates through various phases of clinical trials while burning through cash to fund research and development activities.

Ask drillr about NEONC TECHNOLOGIES HOLDINGS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−5.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

254.73%

ROA (TTM)

−902.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−4.40%

YTD Return

−59.44%

1Y Return

−72.02%

RSI (14)

40.7

vs 50D SMA

−15.10%

vs 200D SMA

−47.22%

Capital & dividendView details →

Debt/Equity

−0.02x

Current Ratio

0.14x

Quick Ratio

0.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

−397.13%

Beats (12Q)

0/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

−123.07%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−47.20M

Op. CF (TTM)

−21.16M

Next earningsNov 12, 2026 →

Latest newsMore news →

NeOnc Technologies Holdings redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for cash at an aggregate stated value of $6.0 million.3d ago

Thomas C. Chen, CEO, Director, and 10% owner of Neonc Technologies Holdings, acquired $39,999 of the company's common stock in two transactions on September 11 and September 14, 2026, through an IRA.5d ago

Similar companies

Fractyl Health, Inc. Common StockGUTS NeurAxis, Inc.NRXS Anixa Biosciences, Inc.ANIX Rallybio CorporationRLYB Atara Biotherapeutics, Inc.ATRA ImmuCell CorporationICCC Find similar companies →

Latest newsMore news →

NeOnc Technologies Holdings redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for cash at an aggregate stated value of $6.0 million.3d ago Thomas C. Chen, CEO, Director, and 10% owner of Neonc Technologies Holdings, acquired $39,999 of the company's common stock in two transactions on September 11 and September 14, 2026, through an IRA.5d ago NeOnc Technologies CEO purchased an additional 37,000 shares of the company's common stock.5d ago